Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer
NCT04633239Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2021
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib in ovarian cancer, sponsored by National Cancer Institute. Primary endpoint: Recommended Phase 2 Dose at 28 days. Started Jul 2021; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04633239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633239.